Bayer bails on chronic cough drug from Evotec, putting the kibosh on lead med in multi-target collaboration

Kyle Blankenship

Bayer and discovery outfit Evotec have long been bosom buddies, cycling through partnerships for the better part of a decade. But now, Bayer is dumping …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bayer bails on chronic cough drug from Evotec, putting the kibosh on lead med in multi-target collaboration

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bay­er bails on chron­ic cough drug from Evotec, putting the ki­bosh on lead med in mul­ti-tar­get col­lab­o­ra­tion

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bayer bails on chronic cough drug from Evotec, putting the kibosh on lead med in multi-target collaboration